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Original Article
Purpose: We reviewed the treatment outcomes and prognostic factors for patients with anal canal carcinoma who were treated 
with curative intent chemoradiotherapy (CRT) at Severance Hospital from 2005 to 2011.
Materials and Methods: Data for 38 eligible patients treated during this period were reviewed. All patients were treated 
with curative intent using radiotherapy (RT) with (n = 35) or without concomitant chemotherapy (n = 3). Among 35 patients who 
received CRT, most of the chemotherapeutic regimens were either 5-fluorouracil (5-FU) plus mitomycin C (23 patients) or 5-FU plus 
cisplatin (10 patients). Recurrence-free survival (RFS), colostomy-free survival (CFS), overall survival (OS), and locoregional control 
(LRC) rates were calculated using the Kaplan-Meier method and survival between subgroups were compared using the log-rank 
test. Cox’s proportional hazard model was used for multivariate analysis.
Results: Over a median follow-up period of 44 months (range, 11 to 96 months), 3-year RFS, CFS, OS, and LRC were 80%, 79%, 
85%, and 92%, respectively. In multivariate analysis, tumor size >4 cm was an independent predicting factor for poorer RFS (hazard 
ratio [HR], 6.35; 95% confidence interval [CI], 1.42 to 28.5; p = 0.006) and CFS (HR, 6.25; 95% CI, 1.39-28.0; p = 0.017), while the 
presence of external iliac lymph node metastasis was an independent prognosticator for poorer OS (HR, 9.32; 95% CI, 1.24 to 70.3; 
p = 0.030). No treatment-related colostomies or deaths occurred during or after treatment.
Conclusion: Curative intent CRT resulted in excellent outcomes that were comparable to outcomes in previous randomized trials. 
No severe treatment-related toxicities were observed.
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Introduction
Squamous cell carcinoma of the anal canal is an uncommon 
malignancy [1], representing only 0.1% of all malignancies in 
Korea [2]. Two phase III trials begun in the 1980s established 
that the combination of 5-fluorouracil (5-FU) and mitomycin 
C (MMC) with radiotherapy (RT) improves tumor control 
[3,4]. The Radiation Therapy Oncology Group (RTOG) 87-
04 trial subsequently confirmed the superiority of 5-FU + 
MMC over 5-FU alone when combined with RT. Results of the 
RTOG 98-11 trial and the Anal Cancer Trial (ACT) II indicate 
no advantage of 5-FU + cisplatin (CDDP) compared to 5-FU 
+ MMC administered during chemoradiotherapy (CRT) [5,6]. 
The RTOG 98-11 and the ACCORD-03 trials tested CDDP-
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based neoadjuvant chemotherapy (NACT) and failed to 
show improvement in either disease-free survival (DFS) or 
colostomy-free survival (CFS) [5,7]. The long-term results of 
the RTOG 98-11 trial show significantly better survival for 5-FU 
+ MMC as compared to 5-FU + CDDP [8]. Additional CDDP-
based maintenance chemotherapy, as tested in the ACT II trial, 
did not improve treatment outcome [6]. Although CDDP-based 
CRT does not improve outcome, it presents an acceptable 
alternative to MMC because it induces less severe hematologic 
toxicity.
Only a few studies report the experience of treating anal 
canal carcinoma in Korean institutions [9-11]. The previous 
report from our institution showed excellent long-term 
survival and preservation of anal function with 5-FU + CDDP-
based CRT with maintenance chemotherapy. Those patients 
were treated from 1995 to 2006; the majority of them received 
conventional radiotherapy and none received the standard 
5-FU + MMC regimen [11]. In the present study, all patients 
received computed tomography (CT) simulation-based three-
dimensional conformal radiotherapy (3-DCRT), except for one 
patient who received intensity modulated radiation therapy 
(IMRT). Moreover, the majority of patients received 5-FU + 
MMC-based CRT without NACT or maintenance chemotherapy. 
We retrospectively analyzed the patients to evaluate treatment 
outcomes and prognostic factors in anal canal carcinoma.
Materials and Methods
1. Patient eligibility
All patients included in this study were diagnosed with 
squamous cell carcinoma of the anal canal and treated 
with curative intent using RT or CRT at Severance Hospital 
between January 2005 and December 2011. Through medical 
records, 47 patients were identified. Of these 47 patients, 5 
patients received less than 20 Gy, 3 had distant metastasis 
at initial diagnosis and one was diagnosed with a double 
primary cancer; these patients were excluded. Among the 
5 patients who received less than 20 Gy, 4 patients refused 
further treatment and 1 patient died of chemotherapy related 
neutropenic septic shock. Patients who had unilateral external 
iliac lymph node metastasis and those who underwent 
transanal excision before curative intent RT or CRT were 
included.
2. Evaluation
Prior to treatment, patients underwent proctoscopy or 
sigmoidoscopy, CT or conventional radiography of the chest, 
CT or magnetic resonance imaging (MRI) of the abdomen 
and pelvis, and 18F-fluorodeoxyglucose-positron emission 
tomography (FDG-PET) with CT. Twenty-eight patients (73.7%) 
received pelvic MRI, 12 patients (31.6%) received FDG-PET/CT, 
and 9 patients (23.7%) received both pelvic MRI and FDG-PET/
CT for initial staging work-up. Excisional biopsy was performed 
in two patients who had palpable inguinal lymph nodes, but 
this was not done routinely. The staging of the tumors was 
done according to the seventh edition of the American Joint 
Committee on Cancer (AJCC) TNM staging system for cancer of 
the anal canal.
3. Treatment
The treatment consisted of curative intent CRT except in 
patients who were intolerant to chemotherapy. MMC (10 
mg/m2) was administered on days 1 and 29 of RT and 5-FU 
infusion (1,000 mg/m2 per 24 hour) on days 1 to 4 and days 
29 to 32 concurrent with radiotherapy. For some patients 
5-FU infusion (1,000 mg/m2 per 24 hour) was given on days 
1 through 5 and days 29 to 33 plus CDDP (80 mg/m2) given 
on days 2 and 30. The patients who received 5-FU + CDDP 
underwent maintenance chemotherapy consisting of the same 
regimen, repeated every 4 weeks for a maximum 4 cycles.
All patients received external beam radiotherapy with 
energies ≥6 MV generated by a linear accelerator using a 
shrinking field technique without a gap. One patient was 
treated with TomoTherapy Hi∙Art II (TomoTherapy Inc., Madison, 
WI, USA). CT simulation, with the patient in the supine position 
and with a full bladder, was mandatory. Gross tumor volume 
included the primary anal tumor and metastatic lymph nodes. 
Clinical target volume was defined as 2 cm to the primary anal 
tumor including the mesorectum, as well as bilateral internal 
and external iliac, bilateral inguinal and presacral nodal 
regions. The clinical target volume was manually edited to 
avoid overlap into bone or nontarget muscles. 
External beam radiotherapy was performed with either 
an anteroposterior-posteroanterior or multifield technique. 
After a dose of 45 Gy in 25 fractions for the whole pelvis, the 
field was reduced to gross tumor volume plus a 2-cm margin 
including the mesorectum to deliver an additional boost of 
5.4 to 14.4 Gy in fractions of 1.8 Gy; the total dose delivered 
to metastatic lymph nodes was no more than 54 Gy. In some 
patients the superior extent of the initial field was reduced at 
30.6 to 36 Gy. Negative inguinal nodes received 36 Gy using 
electrons of 12 to 18 MeV. 
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4. Follow-up
The first assessments of tumor response were made by clinical 
and radiologic evaluation (pelvic CT or MRI) 4 weeks and 6 
months after the end of RT. Response was evaluated according 
to Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria. Patients were seen weekly during treatment and 
every 3 to 6 months thereafter. Acute toxicities were recorded 
according to the National Cancer Institute’s Common Toxicity 
Criteria ver. 3.0 [12] and late toxicities were assessed using 
long-term radiation sequelae LENT-SOMA (Late effect normal 
tissues somatic objective management analytic) classification 
scales [13].
5. Statistical analysis
Locoregional failure was defined as tumor recurrence in the 
anus or regional lymph nodes and recurrences at other sites 
were regarded as distant failure. Recurrence-free survival 
(RFS) was defined from the date of histological diagnosis until 
recurrence or death by any cause and overall survival (OS) was 
measured regardless of the cause of death. CFS was based on 
the date of colostomy or death by any cause, and any patient 
who underwent a colostomy prior to the CRT was excluded 
from analysis. Overall treatment time (OTT) was defined as the 
number of days from the start of RT to the end of treatment. 
Data were analyzed using SPSS ver. 20.0 (SPSS Inc., Chicago, 
IL, USA). RFS, CFS, OS, and the locoregional control (LRC) rates 
were estimated using the Kaplan-Meier method. Differences in 
survival between the groups were tested using a log-rank test. 
All reported p-values are 2-sided and statistical significance 
was defined as p < 0.05. Multivariate analyses were performed 
using Cox proportional hazard models. 
Results
1. Patient characteristics and treatment compliance
Pretreatment characteristics of 38 patients are summarized 
in Table 1. The median age was 58 years (range, 36 to 82 
years). Twenty-five patients (65.8%) were women; 37 patients 
(97%) had the Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 or 1; tumors were larger than 4 cm in 
6 patients (15.8%); 10 patients (26.3%) had T3 or T4 lesions; 
and 23 patients (60.5%) had radiologically or clinically positive 
nodes. The stage of disease was I in 5 patients (13.2%), II in 9 
patients (23.7%), IIIA in 6 patients (15.8%), IIIB in 14 patients 
(36.8%), and IV in 4 patients (10.5%).
RT was temporarily interrupted in 13 patients (34.2%) 
because of toxicity, most commonly dermatitis, but treatment 
was not prematurely terminated in any patient. The median 
dose delivered at first treatment break was 41.4 Gy (range, 
10.8 to 50.4 Gy). The 9 patients who experienced treatment 
break due to skin reaction received a median dose of 41.4 Gy 
(range, 30.6 to 50.4 Gy) at first interruption. The median day of 
interruption during RT was 10 days (range, 1 to 69 days). One 
patient with 69 days of interruption underwent curative intent 
CRT with 50.4 Gy in fractions of 1.8 Gy, but a residual tumor 
Table 1. Patient characteristics (n = 38)
Characteristic No. (%)
Age (yr), median (range)
Female
ECOG performance status
0
1
2
Histologic grade
Well-differentiated 
Moderately-differentiated 
Poorly-differentiated 
Unspecified 
Size (cm), median (range)
T stage
T1 
T2 
T3 
T4 
N stage
N0 
N1 
N2
N3 
M stage
M0 
M1 
Chemotherapy regimen 
Fluorouracil + mitomycin
Fluorouracil + cisplatin
5-fluorouracil
No chemotherapy
Total dose (Gy), median (range)
Duration of radiotherapy (day), median 
(range)
Overall treatment time (day), median 
(range)
58 (36–82)
25 (66)
18 (47)
19 (50)
 1 (3)
 2 (5)
20 (53)
 8 (21)
 8 (24)
2.7 (0.6–6.0)
11 (29)
17 (44.7)
 4 (10.5)
 6 (15.8)
15 (39.5)
 8 (21)
10 (26.3)
 5 (13.2)
34 (89.5)
 4 (10.5)a)
23 (60.5)
10 (26.3)
 2 (5.3)
 3 (7.9)
54 (45–64.8)
46 (33–119)
50 (33–225)
ECOG, the Eastern Cooperative Oncology Group.
a)Patients with unilateral external inguinal lymph node metasta-
sis were included.
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was found at 4-week follow-up. This patient refused surgery 
and received an additional 10.8 Gy to the primary tumor after 
a 4-week rest period, which was not related to treatment 
toxicity. Patients who received more than 54 Gy had more 
treatment breaks compared to patients who had RT doses of 
54 Gy or less, but the difference was not significant (41% vs. 
19%; p = 0.167). Chemotherapy was omitted during RT in 2 
elderly patients and one patient who had undergone kidney 
transplantation. Among the 3 patients who underwent RT 
alone, one received 3 cycles of 5-FU + CDDP after completion 
of RT. Of the 35 patients who underwent concurrent CRT, 
2 received only 5-FU because of advanced age. Six patients 
(15.8%) received 2 to 4 cycles of maintenance chemotherapy 
as 5-FU + CDDP. Hematologic toxicities or poor general 
condition led to chemotherapy dose reductions for 6 patients. 
The treatment characteristics are summarized in Table 1.
2. Treatment response 
The first tumor response evaluation was made by pelvic-CT or 
MRI at 4 weeks after completion of RT. Sixteen patients (42.1%) 
had complete response while 21 patients (55.3%) had partial 
response and one patient had progressive disease. The patient 
who had progressive disease underwent abdominoperineal 
resection (APR) 4 weeks after finishing CRT. At 6 months, 16 
of the 21 partial responders had achieved complete response. 
Among the 5 patients with residual tumor shown radiologically 
at 6 months, 2 underwent biopsy of the primary cancer and 
were confirmed to have no residual tumor, one experienced 
local recurrence at 35 months after treatment, and 2 showed 
no evidence of recurrence. 
3. Colostomy
At the time of last follow-up, 5 patients (13.2%) had had a 
colostomy, 4 of these due to tumor, and one due to underlying 
Crohn’s disease. The patient with Crohn’s disease was excluded 
from analysis. None of the patients had colostomy to address 
treatment complications. The estimated 3-year CFS was 79.4% 
(95% confidence interval [CI], 65.5% to 93.3%) (Fig. 1) and the 
3-year colostomy rate was 8.1% (95% CI, 0% to 17.1%). 
4. Survival and recurrence 
At a median follow-up of 44 months (range, 11 to 96 months), 
32 patients were alive. Four patients had died from progressive 
disease, one patient who had had kidney transplantation 
died from emphysematous pyelonephritis and one died from 
pneumonia. The latter two were free from active anal canal 
carcinoma at the time of death. The 3-year OS was 84.5% (95% 
CI, 71.8% to 97.2%) (Fig. 1). At last follow-up 30 patients were 
alive without recurrence. The estimated 3-year RFS was 80.0% 
(95% CI, 66.5% to 93.5%) and median time to first recurrence 
was 14 months (range, 8 to 39 months) (Fig. 1). 
The estimated 3-year LRC rate was 92.1% (95% CI, 83.3% 
to 100%) and the 3-year distant control rate was 89.0% (95% 
CI, 78.6% to 99.4%). Seven patients (18.4%) experienced 
recurrence, including 3 with locoregional failure, 3 with distant 
failure and one with synchronous locoregional and distant 
failures. Three patients received APR for local recurrence while 
one patient received chemotherapy after APR. One patient who 
had paraaortic lymph node recurrence refused any salvage 
treatment. Another patient with a single metastatic lung 
nodule underwent wedge resection but eventually developed 
pleural metastasis and hematogenous lung metastases. The 
patient with synchronous local and paraaortic lymph node 
recurrence had APR and chemotherapy. She is alive without 
any evidence of local recurrence but with multiple non-
regional lymph node and bone metastases. The characteristics 
of recurrent cases are shown in Table 2.
5. Risk factors
Tumors larger than 4 cm, advanced T stage and the presence 
of external iliac lymph node metastasis were negatively 
associated with treatment outcomes (Table 3). The patients 
Fig. 1. Estimated overall survival (OS), recurrence-free survival 
(RFS), and colostomy-free survival (CFS) of patients with anal 
carcinoma following chemoradiotherapy. a)One patient, who 
underwent colostomy due to underlying Crohn’s disease, was 
excluded from this analysis.
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with tumors larger than 4 cm had significantly worse 3-year 
RFS (50% vs. 88%; p = 0.020), 3-year CFS (50% vs. 87%; p = 
0.022) and 3-year LRC (94% vs. 83%; p = 0.049) in univariate 
analysis (Fig. 2). In multivariate analysis tumor size greater 
than 4 cm was associated with poor RFS (hazard ratio [HR], 
6.35; 95% CI, 1.42 to 28.5; p = 0.006) and CFS (HR, 6.25; 95% 
CI, 1.39 to 28.0; p = 0.017) but not with LRC. Clinical T stage, 
which includes information about tumor size and tumor 
extent, was also negatively associated with 3-year RFS (89% 
vs. 58%; p = 0.033), 3-year CFS (89% vs. 58%; p = 0.040) and 
3-year LRC (96% vs. 80%; p = 0.021). Presence of external 
iliac lymph node metastasis was related to poorer 3-year OS 
in univariate analysis (89% vs. 38%; p = 0.032) and remained 
significant in multivariate analysis (HR, 9.32; 95% CI, 1.24 to 
70.3; p = 0.030) (Table 4). 
Chemotherapy regimen during CRT did not show significant 
association with treatment outcome. Patients who received 
standard CRT with 5-FU + MMC did not differ significantly in 
RFS, CFS, OS, and LRC from patients who did not receive 5-FU 
+ MMC. Patients who received maintenance chemotherapy 
Table 2. Clinical characteristics of patients with recurrent anal canal carcinoma
No. Staging
Initial  
treatment
Total dose 
(Gy)
4-wk 
response
R-duration 
(mo)
Recur site
Salvage treatment/
response
Survival status
1
2
3
4
5
6
7
cT4N3M0
cT3N2M0
cT4N0M0
cT2N0M0
cT2N2M1
cT3N3M0
cT2N2M1
RT alone
CRT 
CRT + APRa)
CRT
CRT + CTx
CRT
CRT
59.4 
54 
61.2 
59.4 
59.4 
54 
55 
PR
CR
PD 
CR 
CR
PR
CR
35
6
9
11
13
18
6
Local
Local
Local, inguinal LN
Local, PALN
PALN, SCL, lung
PALN
Lung
APR/CR
APR/CR
CTx/PD
CTx + APR/PR
CTx/PR
None/PD
Metastasectomy + 
CTx/PD
NED at 96 months
NED at 11 months
DWD at 16 months
AWD at 45 months
DWD at 22 months
DWD at 28 months
DWD at 17 months
R-duration, time to recurrence after initial treatment; RT, radiotherapy; CRT, concurrent chemoradiotherapy; APR, abdominoperineal 
resection; CTx, chemotherapy; PR, partial response; CR, complete response; PD, progressive disease; LN, lymph node; PALN, para-aortic 
lymph node; SCL, supraclavicular lymph node; NED, no evidence of disease; DWD, death with disease; AWD, alive with disease.
a)The patient had progressive disease after CRT and underwent salvage surgery.
Table 3. Univariate analysis for recurrence-free survival, colostomy-free survival, overall survival and locoregional control (n = 38)
Variable No.
3-yr LRC 
(%)
p-value
3-yr RFS 
(%)
p-value
3-yr CFS 
(%)
p-value
3-yr OS 
(%)
p-value
Gender (female vs. male)
Age (>58 vs. ≤58 yr)
ECOG (0 vs. 1 or 2)
Size (≤4 vs. >4 cm)
Histologic grade (WD-MD vs. PD)
T1–T2 vs. T3–T4
N0 vs. N+
External iliac LN (-) vs. LN (+)
Stage I–II vs. III–IV
4-wk response (CR vs. non-CR)
6-mo response (CR vs. PR)a)
Treatment break (≥10 vs. <10 day)
RT duration (≥46 vs. <46 day)
5-FU + MMC vs. others
Maintenance CTx (yes vs. no)
25/13
18/20
18/20
32/6
22/8
28/10
15/23
34/4
14/24
16/22
32/5
7/31
19/19
23/15
32/6
78/85
76/88
83/76
88/50
82/60
89/58
76/82
84/50
81/79
75/84
83/80
86/78
73/90
83/79
83/79
0.902
0.269
0.718
0.020b)
0.945
0.033b)
0.868
0.158
0.644
0.793
0.084
0.984
0.419
0.785
0.461
77/84
87/75
83/75
87/50
81/58
89/58
75/82
83/38
81/79
74/84
82/75
86/77
73/88
82/79
83/78
0.895
0.297
0.673
0.020b)
0.989
0.040b)
0.778
0.152
0.697
0.796
0.090
0.967
0.456
0.887
0.508
81/91
82/86
89/79
90/60
90/58
92/65
83/86
89/38
89/82
86/84
88/75
86/84
79/94
91/79
83/84
0.854
0.961
0.939
0.347
0.328
0.193
0.631
0.032b)
0.739
0.712
0.193
0.639
0.585
0.512
0.671
92/92
88/96
89/95
94/83
86/100
96/80
87/96
91/100
93/92
88/96
94/100
86/94
90/95
87/100
100/91
0.766
0.708
0.310
0.049b)
0.208
0.021b)
0.666
0.516
0.589
0.664
0.361
0.140
0.406
0.433
0.763
OS, overall survival; RFS, recurrence-free survival; CFS, colostomy-free survival; LRC, locoregional control; WD, well-differentiated; MD, 
moderately-differentiated; PD, poorly-differentiated; CR, complete response; PR, partial response; RT, radiotherapy; CTx, chemotherapy.
a)One patient had APR before 6 months for progressive disease and was excluded. b)p < 0.05.
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did not differ significantly in RFS, CFS, OS, or LRC compared to 
patients who did not receive maintenance chemotherapy.
The median RT duration was 46 days (range, 33 to 119 
days) and median OTT was 50 days (range, 33 to 225 days). 
Neither RT duration nor OTT was significantly associated 
with treatment outcome. The RFS, CFS, and OS were not 
reduced in patients with OTT of 50 days or more compared 
to patients whose OTT was less than 50 days. The percentage 
of patients who had OTT ≥ 50 days was significantly higher 
in the subgroup of patients who underwent maintenance 
chemotherapy compared to the patients who did not (100% 
vs. 41%; p = 0.020). RT duration also did not significantly 
influence RFS, CFS, OS or LRC. Significantly more patients who 
had RT duration of 46 days or more received RT doses of more 
than 54 Gy (74% vs. 16%; p < 0.001). Fig. 2. Recurrence-free survival according to tumor size.
Table 4. Multivariate analysis for RFS, CFS, OS, and LRC
Variable
RFS CFS OS LRC
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Size (>4 vs.  
≤ 4 cm)
External iliac  
LN (–) vs. LN (+)
6.35
5.91
1.42–28.52
0.96–36.51
0.006
0.056
6.25
6.01
1.39–28.02
0.97–37.3
0.017
0.054
4.20
9.32
0.58–30.43
1.24–70.32
0.156
0.030
5.07
0.00
0.71–36.01
NA
0.105
0.991
RFS, recurrence-free survival; CFS, colostomy-free survival; OS, overall survival; LRC, locoregional control; LN, lymph node; HR, hazard 
ratio; CI, confidence interval; NA, not-applicable.
Table 5. Acute and late treatment toxicity in patients with anal canal carcinoma
Grade 1 Grade 2 Grade 3 Grade 4 ≥Grade 3 (%)
Acute toxicity
Hematological
Anemia
Thrombocytopenia
Neutropeniaa)
Non-hematological
Skin reaction
Gastrointestinal
Genitourinary
Others
Chronic toxicity
Skin
Gastrointestinal
Genitourinary
Others
27
15
9
8
11
8
8
5
6
5
6
7
1
5
13
11
2
10
2
4
1
0
1
3
7
10
2
0
2
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
2.6
10.5
21.0b)
26.3
5.3
0.0
5.3
0.0
0.0
0.0
0.0
a)There was no febrile neutropenia. b)Among the 8 patients with ≥grade 3 toxicity, 6 patients received fluorouracil + mitomycin C.
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6. Toxicity
The acute and late toxic effects are summarized in Table 5. The 
most frequent grade 3 or 4 toxicity was radiation dermatitis. 
Nine patients had grade 3 or 4 hematologic toxicities and 
8 had neutropenia but there were no febrile neutropenia 
or treatment-related deaths. Among the 23 patients who 
received 5-FU + MMC, 6 patients (26.1%) developed grade 3 
or 4 hematologic toxicities. Of the 15 patients who received 
chemotherapy other than 5-FU + MMC, 2 patients (15.4%) 
had grade 3 or 4 hematologic toxicities but the difference 
between the two groups was not significant (26% vs. 15%; p = 
0.273). Other non-hematologic grade 3 or 4 toxicities included 
diarrhea, anorexia, anal pain and fatigue, each in one patient. 
No grade 3 or 4 late toxicities were observed. Grade 2 late 
toxicities included diarrhea in 2 patients, proctitis in 2, urinary 
incontinence in one and perineal skin fibrosis in 2. 
Discussion and Conclusion
In this cohort of 38 patients who received curative intent CRT 
for squamous cell carcinoma of the anal canal, the treatment 
results were comparable to those reported from other 
studies [3-8,11,14-16]. Although a few studies have reported 
on treatment outcomes with CRT in anal canal carcinoma 
using data from individual Korean institutions, the results 
reported here, gathered from a single, major institution, seems 
meaningful [9,10]. All patients in our study underwent CT 
simulation based 3-DCRT and a majority of them received 
standard 5-FU + MMC-based CRT. 
The CR and survival rates were comparable to values 
previously reported [4,14]. Among the 37 patients whose 
follow-up imaging evaluations at 6 months were available, 32 
patients (86.5%) achieved CR. The previous studies showed 
CR rates of 80% to 95% at 6 to 12 weeks post-CRT [4,6,14]. 
In our study the 3-year RFS, CFS, and OS were 80%, 85%, and 
79%, respectively. Since 2006, most anal canal carcinoma 
patients treated in our institution have received 5-FU + MMC 
concurrently with RT. Prior to 2006, patients received 5-FU + 
CDDP concurrently with CRT plus maintenance chemotherapy. 
Patients who received 5-FU + MMC and patients who received 
other chemotherapy regimens did not differ significantly 
in RFS, CFS or OS. Efforts to improve treatment outcomes 
in anal carcinoma have proceeded throughout the past 
decade. The RTOG 98-11 trial compared the efficacy of the 
standard 5-FU + MMC regimen and that of 5-FU + CDDP 
(induction and concurrent). In the long-term follow-up of this 
trial, the standard 5-FU + MMC regimen showed the more 
favorable DFS and OS [8]. Preliminary results of the ACT II 
trial, which compared MMC-based CRT to CDDP-based CRT, 
showed no difference in response rates or survival between 
the two groups. Randomization of patients to maintenance 
chemotherapy or observation also showed no differences 
in survival [6]. Thus no evidence of benefit in treatment 
outcome has emerged for additional CDDP-based CRT, NACT or 
maintenance chemotherapy. 
In the present study, tumor size and clinical T stage were 
significant prognostic factors for RFS, CFS, and LRC. External 
iliac lymph node involvement was prognostic for OS. Although 
both clinical T stage and tumor size were statistically 
significant in univariate analysis, it was reasonable to include 
only tumor size as a prognostic factor for multivariate 
analysis since clinical T stage is mostly based on tumor size. 
In multivariate analysis tumor size larger than 4 cm was 
independently prognostic for RFS and CFS while external 
iliac lymph node involvement was independently prognostic 
for OS. Although a tendency exists in practice to increase 
the radiation dose according to primary tumor size, patients 
with larger tumors developed more local recurrences, and 
this led to colostomy formation. A previous population-based 
study of 19,199 patients identified male gender, age ≥65 
years, advanced T-stage, lymph node involvement, distant 
metastases, poorly differentiated histology and socioeconomic 
status as negative prognostic factors for survival [17]. 
Analysis in the RTOG 98-11 trial revealed tumor size >5 cm 
(RFS, p = 0.0003; OS, p = 0.0031), clinically positive nodes 
(RFS, p < 0.0001; OS, p < 0.0001), and male gender (RFS, p 
= 0.02; OS, p = 0.016) as independently prognostic factors 
[18]. Recent analysis of the ACT I trial supported lymph node 
status and gender as independently predictive for LRF and OS 
as previously reported [19]. No evidence currently supports 
differential treatment for patients according to prognostic 
factors. Further understanding of clinical variables as related 
to tumor biology is essential for further progress. 
In our study, increases in neither OTT nor RT duration 
significantly influenced either locoregional control or survival. 
Previous retrospective studies show that increases in either 
RT duration or OTT adversely affect local control and survival 
[20,21]. Recent analysis of data from the RTOG 87-04 and 
98-11 trials combined shows that increase in OTT, but not 
RT duration, may adversely affect rates of local failure and 
colostomy [22]. Although the treatment time showed no 
significant association with treatment outcome in our study, 
Kyung Hwan Kim, et al
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RT duration and OTT seems nevertheless to be important in 
local control. Our institutional protocol included no treatment 
break during RT and all patients were treated with 3-DCRT. 
Despite effort to minimize treatment breaks, 13 patients 
(34.2%) required interruption for acute treatment-related 
toxicity. In the interest of reducing acute toxicity, the RTOG 
05-29 trial, multi-institutional phase II study assessed the 
effects of IMRT. Their analysis shows significant reduction in 
acute grade ≥ 2 hematologic, grade ≥ 3 dermatologic, and 
gastrointestinal toxicity using IMRT compared to the results in 
RTOG 98-11 trial [23]. Thus treatment interruptions caused by 
acute toxicity may be reduced by installation of IMRT. 
The limitations of this study include, first, the retrospective 
design. Secondly, the small sample size and the use of multiple 
treatment regimens obscured potential relationships between 
outcomes and treatment factors or risk factors. The patients 
who were more advanced in stage received higher RT doses 
which resulted in longer OTT and RT durations. This may have 
caused the insignificant correlation of the RT factors, such as 
RT dose or treatment time, with treatment outcomes. Ideally, 
patients in the same stage group should be analyzed to 
confirm the influence of RT factors on treatment outcomes, 
but the small sample size limited further analysis in this study. 
Another limitation is the relatively short follow-up period (44 
months), and this may have resulted in the underestimation of 
recurrence. However, a 13-year follow-up update of the ACT I 
trial and another retrospective study, which reported the 30-
year experience from a single institution in treating anal canal 
carcinoma with CRT, showed that 80% to 84% of treatment 
failures occurred within 2 years [15,24].
Our findings show very favorable results, in terms of RFS, 
CFS, and LRC, for the use of CRT with curative intent in 
patients with squamous cell carcinoma of the anal canal. 
The treatment resulted in no treatment-related deaths or 
colostomies. Treatment outcomes for patients with large 
tumors and for those with advanced nodal disease were poor, 
however. For high-risk patients such as these, new agents and 
technologies are needed. Radiosensitizing chemotherapeutics 
and targeted agents currently in development may be useful; 
and IMRT may assist in the intensification of treatment. 
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